BioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced continued acceleration in commercial sales for CyPath® Lung, its noninvasive lung cancer diagnostic, with more than 200% growth year-over-year.

The number of tests sold in the second quarter of 2026 represents an increase of more than 30% over the first quarter of 2026 and more than 200% compared with the second quarter of 2025.